A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients
Standard
A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients : preliminary results of a pilot study. / Lang, P; Schumm, M; Greil, J; Bader, P; Klingebiel, T; Müller, I; Feuchtinger, T; Pfeiffer, M; Schlegel, P-G; Niethammer, D; Handgretinger, R.
in: KLIN PADIATR, Jahrgang 217, Nr. 6, 25.11.2005, S. 334-8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients
T2 - preliminary results of a pilot study
AU - Lang, P
AU - Schumm, M
AU - Greil, J
AU - Bader, P
AU - Klingebiel, T
AU - Müller, I
AU - Feuchtinger, T
AU - Pfeiffer, M
AU - Schlegel, P-G
AU - Niethammer, D
AU - Handgretinger, R
PY - 2005/11/25
Y1 - 2005/11/25
N2 - Transplantation of hematopoietic stem cells from mismatched related donors makes a potential donor available for every child in need of stem cell transplantation. Here, we compare three different graft manipulation methods in patients with leukemias and lymphomas: positive selection of stem cells with either CD34 (n = 39) or CD133-coated magnetic microbeads (n = 14) and a new strategy which depletes T- and B-cells through the use of CD3- and CD19-coated microbeads (n = 11). Median purity of stem cells was comparable after CD34 (+)-selection and CD133 (+)-selection, whereas stem cells were only slightly enriched after CD3 (+)/CD19 (+)-depletion (97.5 %, 93.4 % and 1.02 %). Indirect depletion of T-cells by positive selection resulted in 1 x 10 (4) (median) residual CD3 (+)-cells/kg (0.7-3 x 10 (4)). Patients with CD3/CD19-depleted grafts received 3.2 x 10 (4) (median) (0.7-16 x 10 (4)) residual T-cells/kg. Those grafts also comprised NK-cells (median number: 86 x 10 (6)/kg), dendritic cells and monocytes/granulocytes. Primary engraftment of the stem cell products was comparable after CD34- and CD133-selection (85 and 72 %). In the CD3/CD19 group, 91 % had a primary engraftment. After reconditioning, all patients (64/64) were finally engrafted. Patients with CD34-selected or CD133-selected grafts had similar incidences of a GvHD II-IV (3 and 7 %), whereas a GvHD was slightly increased in patients receiving CD3/CD19-depleted cells (27 %). Reconstitution of CD3 (+) T-cells was faster in the CD3/CD19 group than in the CD34 or CD133 group. These preliminary results indicate, that CD3/CD19-selected grafts may be advantageous regarding engraftment and immunoreconstitution. Since effector cell with potential antileukemic activity are cotransfused, such grafts may be suited in particular for patients with insufficient remission.
AB - Transplantation of hematopoietic stem cells from mismatched related donors makes a potential donor available for every child in need of stem cell transplantation. Here, we compare three different graft manipulation methods in patients with leukemias and lymphomas: positive selection of stem cells with either CD34 (n = 39) or CD133-coated magnetic microbeads (n = 14) and a new strategy which depletes T- and B-cells through the use of CD3- and CD19-coated microbeads (n = 11). Median purity of stem cells was comparable after CD34 (+)-selection and CD133 (+)-selection, whereas stem cells were only slightly enriched after CD3 (+)/CD19 (+)-depletion (97.5 %, 93.4 % and 1.02 %). Indirect depletion of T-cells by positive selection resulted in 1 x 10 (4) (median) residual CD3 (+)-cells/kg (0.7-3 x 10 (4)). Patients with CD3/CD19-depleted grafts received 3.2 x 10 (4) (median) (0.7-16 x 10 (4)) residual T-cells/kg. Those grafts also comprised NK-cells (median number: 86 x 10 (6)/kg), dendritic cells and monocytes/granulocytes. Primary engraftment of the stem cell products was comparable after CD34- and CD133-selection (85 and 72 %). In the CD3/CD19 group, 91 % had a primary engraftment. After reconditioning, all patients (64/64) were finally engrafted. Patients with CD34-selected or CD133-selected grafts had similar incidences of a GvHD II-IV (3 and 7 %), whereas a GvHD was slightly increased in patients receiving CD3/CD19-depleted cells (27 %). Reconstitution of CD3 (+) T-cells was faster in the CD3/CD19 group than in the CD34 or CD133 group. These preliminary results indicate, that CD3/CD19-selected grafts may be advantageous regarding engraftment and immunoreconstitution. Since effector cell with potential antileukemic activity are cotransfused, such grafts may be suited in particular for patients with insufficient remission.
KW - Adolescent
KW - Adult
KW - Antigens, CD
KW - Antigens, CD19
KW - Antigens, CD3
KW - Antigens, CD34
KW - Cell Count
KW - Child
KW - Child, Preschool
KW - Female
KW - Glycoproteins
KW - Haploidy
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Infant
KW - Leukemia
KW - Lymphocyte Depletion
KW - Lymphoma
KW - Male
KW - Microspheres
KW - Peptides
KW - Pilot Projects
KW - Survival Rate
U2 - 10.1055/s-2005-872529
DO - 10.1055/s-2005-872529
M3 - SCORING: Journal article
C2 - 16307419
VL - 217
SP - 334
EP - 338
JO - KLIN PADIATR
JF - KLIN PADIATR
SN - 0300-8630
IS - 6
ER -
